GGrantIndex
← Leaderboards

Evan D Kharasch

University Of Washington

Google Scholar ↗PubMed ↗ORCID ↗
$17,406,013
Attributed
$17,406,013
Total exposure
18
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.5M · FY2005–21
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$14,606,013 · 17
FDA$2,800,000 · 1

By mechanism

R01$11,154,155 · 5
U01$2,800,000 · 1
M01$2,065,184 · 11
K24$1,386,674 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Washington

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchMethadoneDrug InteractionsCytochrome P450Pharmaceutical PreparationsDrug MetabolismHuman SubjectIntestinesMetabolismDoseCyp3a4 GeneIn VivoHepaticClinically SignificantDrug KineticsIn VitroProgramsClinical EffectAids/Hiv ProblemAffectLiverOpioidComplexCytochromes

Grant awards (58)

OPTIMIZING OUTPATIENT ANESTHESIA: IMPROVING ANALGESIA AND REDUCING OPIOID MISADVENTURE$505,171
R01 · FY2021 · DA · contact PI
OPTIMIZING OUTPATIENT ANESTHESIA: IMPROVING ANALGESIA AND REDUCING OPIOID MISADVENTURE$559,927
R01 · FY2020 · DA · contact PI
OPTIMIZING OUTPATIENT ANESTHESIA: IMPROVING ANALGESIA AND REDUCING OPIOID MISADVENTURE$558,182
R01 · FY2018 · DA · contact PI
OPTIMIZING OUTPATIENT ANESTHESIA: IMPROVING ANALGESIA AND REDUCING OPIOID MISADVENTURE$566,187
R01 · FY2017 · DA · contact PI
BIOEQUIVALENCE AND CLINICAL IMPLICATIONS OF GENERIC BUPROPION$1,000,000
U01 · FY2015 · FD · contact PI
BIOEQUIVALENCE AND CLINICAL IMPLICATIONS OF GENERIC BUPROPION$1,000,000
U01 · FY2014 · FD · contact PI
BIOEQUIVALENCE AND CLINICAL IMPLICATIONS OF GENERIC BUPROPION$800,000
U01 · FY2013 · FD · contact PI
METHADONE AND HIV DRUG INTERACTIONS$561,637
R01 · FY2012 · DA · contact PI
ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS$328,423
R01 · FY2012 · DA · contact PI
METHADONE AND HIV DRUG INTERACTIONS$571,721
R01 · FY2011 · DA · contact PI
ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS$328,423
R01 · FY2011 · DA · contact PI
METHADONE AND HIV DRUG INTERACTIONS$574,344
R01 · FY2010 · DA · contact PI
ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS$338,580
R01 · FY2010 · DA · contact PI
Opioids in Cancer Pain & Drug Abuse: Optimizing Therapy$167,165
K24 · FY2010 · DA · contact PI
METHADONE AND HIV DRUG INTERACTIONS$565,729
R01 · FY2009 · DA · contact PI
ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS$342,000
R01 · FY2009 · DA · contact PI
Novel noninvasive assessment of cytochrome P450 activity$295,184
R01 · FY2009 · GM · contact PI
METHADONE AND HIV DRUG INTERACTIONS$560,183
R01 · FY2008 · DA · contact PI
ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS$342,000
R01 · FY2008 · DA · contact PI
Novel noninvasive assessment of cytochrome P450 activity$295,184
R01 · FY2008 · GM · contact PI
Opioids in Cancer Pain & Drug Abuse: Optimizing Therapy$164,893
K24 · FY2008 · DA · contact PI
Opioids in Cancer Pain & Drug Abuse: Optimizing Therapy$9,139
K24 · FY2008 · DA · contact PI
Novel noninvasive assessment of cytochrome P450 activity$295,427
R01 · FY2007 · GM · contact PI
Opioids in Cancer Pain & Drug Abuse: Optimizing Therapy$164,813
K24 · FY2007 · DA · contact PI
METHADONE AND HIV/AIDS DRUG INTERACTIONS$77,179
M01 · FY2007 · RR · contact PI
CYP3A PROBES AND HEPATIC BLOOD FLOW$3,794
M01 · FY2007 · RR · contact PI
CYP3A ACTIVITY AND DRUG EFFECTS$1,898
M01 · FY2007 · RR · contact PI
CYP2B6 ACTIVITY AND DRUG EFFECTS$1,491
M01 · FY2007 · RR · contact PI
Novel noninvasive assessment of cytochrome P450 activity$313,302
R01 · FY2006 · GM · contact PI
Opioids in Cancer Pain & Drug Abuse: Optimizing Therapy$164,419
K24 · FY2006 · DA · contact PI
METHADONE AND HIV/AIDS DRUG INTERACTIONS$30,784
M01 · FY2006 · RR · contact PI
CYP3A PROBES AND HEPATIC BLOOD FLOW$833
M01 · FY2006 · RR · contact PI
METHADONE AND HIV/AIDS DRUG INTERACTIONS$940,505
M01 · FY2005 · RR
Methadone and HIV drug interactions$362,468
R01 · FY2005 · DA
Opioids in Cancer Pain &Drug Abuse: Optimizing Therapy$168,995
K24 · FY2005 · DA
Opioids in Cancer Pain &Drug Abuse: Optimizing Therapy$4,172
K24 · FY2005 · DA
METHADONE AND HIV/AIDS DRUG INTERACTIONS$897,904
M01 · FY2004 · RR
Methadone and HIV drug interactions$377,863
R01 · FY2004 · DA
Pharmacodynamics surrogates of alfentanil disposition$87,612
M01 · FY2004 · RR
Methadone and HIV drug interactions$378,998
R01 · FY2003 · DA
OPIOIDS IN CANCER PAIN &DRUG ABUSE--OPTIMIZING THERAPY$136,191
K24 · FY2003 · DA
Methadone and HIV drug interactions$361,448
R01 · FY2002 · DA
Novel noninvasive assessment of cytochrome P450 activity$288,800
R01 · FY2002 · GM
ANESTHETIC RENAL METABOLISM--MECHANISMS AND CONSEQUENCES$256,796
R01 · FY2002 · DK
OPIOIDS IN CANCER PAIN &DRUG ABUSE--OPTIMIZING THERAPY$124,398
K24 · FY2002 · DA
Methadone and HIV drug interactions$47,313
R01 · FY2002 · DA
Methadone and HIV drug interactions$409,666
R01 · FY2001 · DA
Novel noninvasive assessment of cytochrome P450 activity$277,822
R01 · FY2001 · GM
ANESTHETIC RENAL METABOLISM--MECHANISMS AND CONSEQUENCES$249,320
R01 · FY2001 · DK
OPIOIDS IN CANCER PAIN &DRUG ABUSE--OPTIMIZING THERAPY$144,818
K24 · FY2001 · DA
ANESTHETIC RENAL METABOLISM--MECHANISMS AND CONSEQUENCES$242,057
R01 · FY2000 · DK
OPIOIDS IN CANCER PAIN &DRUG ABUSE--OPTIMIZING THERAPY$137,671
K24 · FY2000 · DA
DISULFIRAM EFFECTS ON DRUG METABOLISM$3,864
M01 · FY2000 · RR
DISULFIRAM EFFECTS ON DRUG METABOLISM$3,864
M01 · FY2000 · RR
MENSTRUAL CYCLE VARIABILITY IN ALFENTANIL PHARMACOKINETICS$3,864
M01 · FY2000 · RR
MENSTRUAL CYCLE VARIABILITY IN ALFENTANIL PHARMACOKINETICS$3,864
M01 · FY2000 · RR
DISULFIRAM EFFECT ON COUMARIN METABOLISM$3,864
M01 · FY2000 · RR
DISULFIRAM EFFECT ON COUMARIN METABOLISM$3,864
M01 · FY2000 · RR